Human T-lymphotropic virus types I and II are retroviral infections that affect T-cells. HTLV-I was the first human retrovirus identified, isolated in 1978 from a patient with cutaneous T-cell lymphoma. A closely related virus, HTLV-II, was later isolated from a patient with hairy cell leukemia. Both viruses are highly cell associated, infect lymphocytes, and cause lifelong infections, although most of these infections remain asymptomatic. Approximately 2% to 5% of HTLV-I-infected individuals develop adult T-cell leukemia/lymphoma after a lag of 20 to 30 years. A smaller percentage develop a neurologic disease called HTLV-associated myelopathy or tropical spastic paraparesis. HTLV-II disease associations remain unclear. Both infections are thought to be spread through blood and sexual contact. FDA-licensed donor tests for HTLV infection are serologic screening assays for IgG antibody to HTLV-I and HTLV-II. FDA-licensed supplemental tests are also available.
AABB Updates JEV Fact Sheet After Probable Transmission via Organ Transplantation
April 14, 2026
AABB Issues Interim Standards Focusing on Infectious Disease Testing for Facilities Outside the US
April 06, 2026
Oropouche Virus RNA Detected in Blood Donors During 2023–24 Brazil Outbreak
March 31, 2026